A cellular recycling process called autophagy helps determine whether pancreatic cancer cells grow quickly or hunker into survival mode to resist treatment, a study…
News
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions…
GYNECOLOGICAL CANCER
Elenagen helps women with ovarian cancer live 1 year longer
Adding Elenagen, Curelab Oncology’s experimental anticancer medication, to gemcitabine chemotherapy may help women with treatment-resistant ovarian cancer live significantly longer. Those are the results…
A new, ultrasensitive blood test checks for cancer cells remaining in the body after multiple myeloma treatment using blood samples instead of more invasive bone…
Enrollment is now complete for an early clinical study assessing the safety and tolerability of SENTI-202, Senti Biosciences’ cell therapy candidate for adults with…
PANCREATIC CANCER
FDA approves electrical field therapy Optune Pax for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved Novocure’s Optune Pax, a type of Tumor Treating Fields (TTFields) therapy, as a treatment for…
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning…
GYNECOLOGICAL CANCER
Ovarian cancer drug lira-cel extends survival ‘far longer’ than expected
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel,…
Anito-cel (anitocabtagene autoleucel), a cell therapy in clinical development as a potential treatment for myeloma, may be less likely to cause side effects than…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people…
